SMTL ID : 6wx2.2 (1 other biounit)

Vaccine-elicited mouse FP-targeting neutralizing antibody vFP16.02 with F60P mutation on light chain in complex with HIV fusion peptide (residue 512-519)

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.39 Å

Oligo State

hetero-1-1-mer

Ligands

1 x ALA- VAL- GLY- ILE- GLY- ALA- VAL- PHE: fusion peptide(Non-covalent)

ALA-VAL-GLY-ILE-GLY-ALA-VAL-PHE.1: 16 residues within 4Å: Chain A: E.33, A.50, D.52, S.55, A.57, S.58, A.59, L.99, Y.101, F.102, G.103 Chain B: Y.31, Y.37, E.39, G.96, Y.101 14 PLIP interactions: 7 interactions with chain A, 7 interactions with chain B Hydrophobic interactions: A:L.99, A:F.102, A:F.102, B:Y.31, B:Y.31, B:Y.37, B:Y.101 Hydrogen bonds: A:E.33, A:E.33, A:F.102, A:G.103, B:E.39, B:G.96, B:Y.101

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Madan, B. et al., Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody. Proc.Natl.Acad.Sci.USA (2021)

Release Date

2021-03-17

Peptides

vFP16.02 antibody heavy chain: A
vFP16.02 antibody light chain: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
H

B
L

vFP16.02 antibody heavy chain

vFP16.02 antibody light chain

Related Entries With Identical Sequence